Serina Therapeutics Inc. (SER)
NYSE: SER
· Real-Time Price · USD
5.28
-0.22 (-4.00%)
At close: Aug 15, 2025, 3:59 PM
5.41
2.46%
After-hours: Aug 15, 2025, 06:12 PM EDT
Serina Therapeutics Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 130K | n/a | -14K | 14K | 51K | 5K | 3.07M | 67K | 9K | 10K | 8K | 9K | 12K | 5K | 2K | 24K | 37K | 56K |
Cost of Revenue | 16K | 17K | n/a | 56K | 57K | 25K | -47K | 66K | 37K | 34K | 34K | 38K | 39K | 34K | 34K | 34K | 46K | 36K |
Gross Profit | 114K | -17K | -70K | -42K | -6K | -20K | 3.08M | 1K | -28K | -24K | -26K | -29K | -27K | -29K | -32K | -10K | -9K | 20K |
Operating Income | -5.57M | -5.86M | -5.55M | -5.31M | -3.87M | -2.32M | 241K | -1.46M | -1.89M | -2.16M | -1.78M | -1.55M | -1.59M | -2.05M | -1.89M | -1.67M | -2.21M | -2.29M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -6.46M | -4.82M | -2.75M | 1.38M | 5.18M | -9.44M | 1.05M | 1.75M | -2.68M | -3.29M | -2.76M | -2.44M | -2.62M | -2.71M | -2.16M | -1.96M | -2.48M | -1.99M |
Net Income | -6.45M | -4.81M | -2.74M | 1.41M | 5.2M | -9.44M | -3.46M | -5.4M | -2.67M | -3.28M | -2.7M | -2.44M | -2.62M | -2.71M | -2.16M | -1.96M | -2.47M | -2.09M |
Selling & General & Admin | 2.53M | 2.91M | 3.17M | 2.91M | 2.32M | 1.22M | 1.94M | 2.17M | 1.73M | 1.99M | 1.58M | 1.39M | 1.34M | 1.66M | 1.52M | 1.42M | 1.75M | 2.02M |
Research & Development | 3.15M | 2.95M | 2.37M | 2.42M | 1.59M | 1.1M | 907K | 185K | 128K | 141K | 175K | 129K | 226K | 363K | 343K | 243K | 448K | 291K |
Other Expenses | n/a | n/a | 14K | -14K | -51K | -23K | -6K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 5.68M | 5.86M | 5.55M | 5.31M | 3.87M | 2.3M | 2.84M | 2.36M | 1.86M | 2.13M | 1.76M | 1.52M | 1.56M | 2.02M | 1.86M | 1.66M | 2.2M | 2.31M |
Interest Expense | 9K | n/a | 17K | 16K | 242K | 99K | 176K | 100K | 195.7K | 86K | 978K | 923K | 863K | 1.11M | 295K | 285K | 274K | 243K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.28M | 1.26M | 1.4M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 5.7M | 5.86M | 5.55M | 5.31M | 3.92M | 2.32M | -204K | 2.42M | 1.9M | 2.17M | 1.79M | 1.56M | 1.6M | 2.06M | 1.89M | 1.7M | 2.24M | 2.35M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | -2K | n/a | -10K | -8K | n/a | -1K | n/a | -1K | -1K | n/a | -1K | n/a |
Shares Outstanding (Basic) | 10M | 9.76M | 8.85M | 8.85M | 8.51M | 2.79M | 1.08M | 2.19M | 1.08M | 1.08M | 1.08M | 1.08M | 1.08M | 1.08M | 1.08M | 1.08M | 1.08M | 1.07M |
Shares Outstanding (Diluted) | 10M | 9.76M | 10.75M | 10.75M | 10.16M | 2.79M | 1.08M | 7.58M | 1.08M | 1.08M | 1.08M | 1.08M | 1.08M | 1.08M | 1.08M | 1.08M | 1.08M | 1.07M |
EPS (Basic) | -0.64 | -0.49 | -0.31 | 0.16 | 0.61 | -3.38 | -3.2 | 0.80 | -2.47 | -3.04 | -2.51 | -2.26 | -2.43 | -2.51 | -2 | -1.81 | -2.29 | -1.95 |
EPS (Diluted) | -0.64 | -0.49 | -0.25 | 0.13 | 0.51 | -3.38 | -3.2 | 0.23 | -2.47 | -3.04 | -2.51 | -2.26 | -2.43 | -2.51 | -2 | -1.81 | -2.29 | -1.95 |
EBITDA | -6.44M | -4.8M | -2.68M | 1.45M | 5.48M | -9.31M | 1.23M | 1.91M | -1.85M | -2.15M | -1.75M | -1.52M | -1.72M | -2.02M | -1.86M | -1.64M | -2.17M | -1.72M |
EBIT | -6.45M | -4.82M | -2.73M | 1.4M | 5.42M | -9.34M | 1.23M | 1.85M | 916K | 1.74M | -1.78M | -1.51M | -1.75M | -1.59M | -1.86M | -1.67M | -2.2M | -1.75M |
Depreciation & Amortization | 16K | 17K | 56K | 56K | 57K | 25K | 6K | 54K | 32K | 33K | 33K | 33K | 33K | 33K | 33K | 32K | 33K | 33K |